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Renal Denervation in Heart Failure Essential hypertension and heart failure are characterized by excessive central sympathetic drive. The 
contribution of the kidney´s afferent nerves, as an underlying cause of elevated central sympathetic drive, and the consequences of excessive 
efferent sympathetic signals to the kidney itself, as well as other organs, identify the renal sympathetic nerves as a target for diseases linked by 
excessive sympathetic drive. Heart failure associated with reduced systolic function or edema or both is characterized by substantial neurohormonal 
activation in heart, kidney and skeletal muscle-
background: This pilot study evaluated renal and left ventricular function after renal denervation for heart failure in patients with non ischemic 
cardiomyopathy METHOD: 15 patients (mean age 68 years) with chronic systolic heart failure with a mean EF of 24%±5 a mean BP on referral of 
112/65 mmHg on maximal tolerated heart failure therapy. A six minute walk test (6MWT) was performed at baseline. eGFR ≥ 40 (ml-min-1.73mts2). 
BNP 1500ng/dl ± 300. Follow-up was weekly for 2 weeks, and then monthly. 
results: Significant haemodynamic findings were noted during the acute phase post renal denervation. There was a non-significant trend to 
blood pressure (BP) reduction (Δsystolic -5.1 ± 6.0 mmHg, p=0.35; Δdiastolic -0.6 ± 4.0 mmHg, p=0.88).Ejection fraction disclosed a significant 
improvement (-EF+10±5, p<0.01). No hypotensive or syncopal episodes were reported. Renal function remained stable. All 15 patients described 
themselves as symptomatically improved. Two months after the procedure there was no change in the BP, no significant change in the eGFR .BNP 
390ng/dl ± 200. EF did not demonstrate any changes. Six Class IV NYHA patients converted to Class III. Six minutes walking test demonstrated 
marked improvement. Renal denervation is a useful tool for the treatment of chronic heart failure.
